Journal of the National Comprehensive Cancer Network · 2021 · 530 citations · 49 references
MedicineOncologyUrologyGenitourinary OncologyProstate DiseaseUrologic OncologyCancer StagingMetastatic Cancer ManagementMetastatic Disease ManagementMetastatic Disease TreatmentProstate CancerProstate SurgeryCastration-resistant Prostate Cancer TherapyDisease MonitoringMetastatic Castration-resistant Prostate CancerMetastatic Disease MonitoringProstate Cancer DiagnosisProstate Cancer MonitoringProstate Cancer Risk StratificationRecurrent Metastatic Disease
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, and metastatic disease. Recommendations for disease monitoring and treatment of recurrent disease are also included. The NCCN Prostate Cancer Panel meets annually to reevaluate and update their recommendations based on new clinical data and input from within NCCN Member Institutions and from external entities. This article summarizes the panel's discussions for the 2021 update of the guidelines with regard to systemic therapy for metastatic castration-resistant prostate cancer.
49
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2020 · 21.4K citations · Full text
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Hannah Farmer, Nuala McCabe, Christopher J. Lord et al. · Nature · 2005 · 6.7K citations
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le, Jennifer N. Durham, Kellie N. Smith et al. · Science · 2017 · 6.6K citations
Life Sciences, Immunology, Oncology +17
Integrative Clinical Genomics of Advanced Prostate Cancer
Dan R. Robinson, Eliezer M. Van Allen, Yi-Mi Wu et al. · Cell · 2015 · 3.6K citations · Full text
Aurélien Marabelle, Dung T. Le, Paolo A. Ascierto et al. · Journal of Clinical Oncology · 2019 · 3K citations · Full text
Life Sciences, Immunology, Oncology +17